Oppenheimer maintains Immunovant stock rating on next-gen drug focus

Investing_ng | 03-04-2026 04:13am |

Oppenheimer maintains Immunovant stock rating on next-gen drug focus

Related Articles

Adamawa Approves Over N13.9bn Road, Educ... Business,top
Dollar to Naira exchange rate today, Jul... Business,top
EFCC Seeks Stronger Alliance With ICPC, ... Business,top
Four Abducted, One Killed In Bauchi Atta... Top,crime
Plateau PDP kicks over proposed bill for... Politics,top
Lighting The Future: The Socio-Economic ... Top,business,environment

Stay Updated with the Latest News!

Don't miss out on breaking stories and in-depth articles.

See the latest News